Comment on "Risk analysis of metformin use in prostate cancer: a national population-based study"
Aging Male
.
2024 Dec;27(1):2340087.
doi: 10.1080/13685538.2024.2340087.
Epub 2024 Apr 8.
Authors
Shih-Wei Lai
1
2
,
Bing-Fang Hwang
3
,
Chiu-Shong Liu
1
2
,
Kuan-Fu Liao
4
5
Affiliations
1
Department of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
2
Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
3
Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan.
4
College of Medicine, Tzu Chi University, Hualien, Taiwan.
5
Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan.
PMID:
38590117
DOI:
10.1080/13685538.2024.2340087
No abstract available
MeSH terms
Diabetes Mellitus, Type 2*
Humans
Male
Metformin* / therapeutic use
Prostatic Neoplasms* / epidemiology
Risk Assessment
Substances
Metformin